News >

Targeted Therapies Emerging for Less-Common NSCLC Subtypes

Caroline Seymour
Published: Wednesday, Jul 25, 2018

Jessica Bauman, MD

Jessica Bauman, MD

Targeted therapies against EGFR mutations and ALK rearrangements have been associated with promising outcomes in non–small cell lung cancer (NSCLC), and recent data suggest that similar success is on the horizon for patients with BRAF, ROS1, and RET abnormalities, explained Jessica Bauman, MD.

abnormalities in NSCLC.

OncLive: Can you provide an overview of your presentation on BRAF-mutant, ROS1-rearranged, and RET-modified NSCLC?

Bauman: I spoke about some of the other targets in NSCLC that have become more important when thinking about new diagnoses of metastatic NSCLC. We spoke about BRAF, ROS1, and RET, all of which are associated with new targeted therapies. BRAF, ROS1, and RET are found in 1% to 5% of lung adenocarcinomas. We know that the classic success stories in lung cancer in the last decade have been with EGFR and ALK mutations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x